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BACKGROUND: Comorbidity and socioeconomic status (SES) may be related among cancer patients.
METHOD: Population-based cancer registry study among 72 153 patients diagnosed during 1997–2006.
RESULTS: Low SES patients had 50% higher risk of serious comorbidity than those with high SES. Prevalence was increased for
each cancer site. Low SES cancer patients had significantly higher risk of also having cardiovascular disease, chronic obstructive
pulmonary diseases, diabetes mellitus, cerebrovascular disease, tuberculosis, dementia, and gastrointestinal disease. One-year survival
was significantly worse in lowest vs highest SES, partly explained by comorbidity.
CONCLUSION: This illustrates the enormous heterogeneity of cancer patients and stresses the need for optimal treatment of cancer
patients with a variety of concomitant chronic conditions.
British Journal of Cancer (2010) 103, 1742–1748. doi:10.1038/sj.bjc.6605949 www.bjcancer.com
Published online 26 October 2010
& 2010 Cancer Research UK
Keywords: socioeconomic status; comorbidity; chronic disease; survival









































People of a lower socioeconomic status (SES) generally have
poorer health status and higher mortality than people of higher
SES (Jemal et al, 2008; Mackenbach et al, 2008), also with respect
to cancer, with in general higher incidence rate of all cancers
combined among people from lower socioeconomic groups
(Dalton et al, 2008). A differential distribution of known risk
factors for specific neoplasms between SES groups seems a likely
explanation for the above inequalities. For example, the prevalence
of smokers has become higher among lower classes (Lahelma et al,
1997; Stronks et al, 1997), probably resulting in higher rates
of cancer of the lung, larynx, mouth, pharynx, oesophagus, and
bladder (Siemiatycki et al, 1995; Stellman and Resnicow, 1997;
Tyczynski et al, 2003). However, smoking is not only related to
cancer but also to chronic obstructive pulmonary diseases
(COPD) and cardiovascular diseases (Doll et al, 1994). Hence,
the high prevalence of comorbidity among lung cancer patients
(Janssen-Heijnen et al, 1998). Socioeconomic status may thus
be associated with comorbidity among cancer patients. Thus,
medical doctors are presented with a heterogeneous group of
cancer patients, for whom appropriate individual treatment must
be chosen, taking concomitant conditions into account (Ayanian
et al, 2003; Lash et al, 2003; Janssen-Heijnen et al, 2004; Lemmens
et al, 2005; Louwman et al, 2005; van Spronsen et al, 2005).
We studied in a large population-based group of cancer patients
the prevalence of comorbidity according to SES, not only by
number of concomitant diseases, but also for specific diseases that
affect patients with the various tumour sites.
MATERIALS AND METHODS
The Eindhoven Cancer Registry records data on all patients newly
diagnosed with cancer in the south of the Netherlands (2.4 million
inhabitants, 15% of the Dutch population); it also records serious
comorbidity according to an adaptated list (Charlson et al, 1987).
Chronic obstructive pulmonary diseases, cardio- and cerebro-
vascular diseases, peripheral arterial disease, other malignancies,
and diabetes mellitus, connective tissue diseases, rheumatoid
arthritis, kidney, bowel, and liver diseases, dementia, tuberculosis
and other chronic infections were also recorded. For most analyses
peripheral arterial disease was included in the cardiovascular
diseases, although gastrointestinal diseases were grouped (gastric
diseases, Crohn’s disease, ulcerative colitis, liver cirrhosis, and
hepatitis). Comorbidity was defined as life-shortening disease that
was present at the time of cancer diagnosis and/or received
treatment or surveillance. Trained registry personnel actively
collect data on diagnosis, staging, and treatment from the medical
records after notification by pathologists and medical registration
offices. Previous admissions, letters from and to general practi-
tioners and other specialists, the medical history and preoperative
screening were used as sources.
Patients with cancer of the oesophagus, stomach, colon or
rectum, pancreas, lung, melanoma, breast, cervix uteri, corpus
uteri, ovary, prostate, bladder, kidney, and non-Hodgkin’s
lymphoma (NHL), newly diagnosed between 1997 and 2006
(n¼ 72 153), were included in this study; cancers diagnosed at
autopsy (n¼ 369) were excluded.
Statistics Netherlands developed an indicator of SES, using
individual fiscal data on the economic value of the home
and household income, and is provided at aggregated level
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for each postal code (covering an average of 17 households).
Socioeconomic status was categorised as low (deciles 1–3),
medium (deciles 4–7), or high social class (deciles 8–10), and a
separate class for postal codes for a long-term care providing
institution (such as a nursing home; van Duijn and Keij, 2002).
We calculated the distribution of cancer patients across socio-
economic strata according to tumour localisation, also by gender
and age. Patients for whom the SES was unknown (n¼ 766, 1%) or
for whom the postal code included a care providing institution
(n¼ 3569, 5%), as well as those with unknown comorbidity
(n¼ 8399, 12%) were excluded from the analyses of SES and
comorbidity. Differences in distribution were tested with the
w2 test. Logistic regression analyses of the odds of having a specific
concomitant disease were performed age- and gender-adjusted for
all tumour sites combined, and according to tumour site for four
concomitant diseases separately; cardiovascular disease, COPD,
diabetes mellitus, and gastrointestinal disease. Statistical
significance of an overall effect of SES on the prevalence of a
specific condition was tested using the w2-likelihood ratio test.
Crude 1-year survival rates were calculated for all studied tumours
combined and for the most important tumour sites separately.
Cox’s regression models were used to compute multivariate rates
(hazard ratio¼HR) and 95% confidence intervals (95% CI).
The relative contribution (%) of adding comorbidity to the model
was calculated as follows: ((HR model AHR model B)/(HR model
A1)) 100, where A is the basic model (age- and gender-
adjusted) and in model B comorbidity is added to model A.
All statistical analyses were performed using SAS V9.12 (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Male cancer patients were older than female patients (Table 1), the
median age being 69 and 64 years, respectively (Po0.0001). At the
time of the diagnosis of the cancer 71% of male and 58% of female
cancer patients had at least one concomitant disease. The most
frequent concomitant condition for males with cancer was
cardiovascular disease (23%), for women hypertension (20%),
among cancer patients older than 70 the prevalence of these
diseases was 34% and 31%, respectively. In the subgroup of cancer
patients with two or more concomitant diseases, the most frequent
combination of diseases among males was cardiovascular
disease with hypertension (14%) and in females diabetes with
hypertension (21%).
The proportion of patients by SES varied for the different
tumour sites (Table 2). Patients under age 70 with stomach, lung,
bladder, or cervical cancer more often had low SES. High SES
was more frequent among patients with melanoma or breast,
colorectal, or prostate cancer in this age group.
Among patients aged 70þ with cancer of the oesophagus,
stomach, or lung, low SES was clearly over-represented. High SES
was more frequent among patients with prostate cancer or NHL.
For all tumour localisations the proportion of patients without
comorbidity was highest in the high SES group (Figure 1).
Table 1 Description of all cancer patients diagnosed with selected
tumours between 1997 and 2006 in the Eindhoven Cancer Registry
Males Females Total
n % n % n %
Tumour localisation
Oesophagus 1079 3 398 1 1477 2
Stomach 1723 5 1032 3 2755 4
Colorectal 6815 19 6014 17 12 829 18
Pancreas 907 2 849 2 1756 2
Lung 9354 26 3591 10 12 945 18
Melanoma 1405 4 1899 5 3304 5
Breast — 14 859 41 14 859 20
Cervix uteri — 725 2 725 1
Corpus uteri — 2128 6 2128 3
Ovary — 1540 4 1540 2
Prostate 9987 27 — 9987 14
Kidney 1201 3 806 2 2007 3
Urinary bladder 2306 6 679 2 2985 4
Non-Hodgkin’s lymphoma 1846 5 1413 4 3259 4
Age
o45 1156 3 3884 11 5040 7
45–59 6624 18 10 578 29 17 202 24
60–74 18 984 52 13 142 37 32 126 44
475 9859 27 8329 23 18 188 25
SES
Low 9518 26 9953 28 19 471 27
Intermediate 14 309 39 13 824 38 28 133 39
High 10 812 30 9741 27 20 553 28
Institution 1569 4 2032 6 3601 5
Unknown 415 1 383 1 798 1
Comorbidity
Number of concomitant diseases
0 10 688 29 14 826 41 25 514 35
1 10 775 29 9353 26 20 128 28
42 10 992 30 7050 20 18 042 25
Unknown 4168 11 4704 13 8872 12
Concomitant diseasea
Previous cancer 4460 12 3565 10 7977 11
Cardiovascular disease 8353 23 3854 11 12127 17
Peripheral arterial disease 3445 9 1358 4 4767 7
COPD 5347 15 2674 7 7994 11
Hypertension 6367 17 7184 20 13 462 19
Diabetes mellitus 3586 10 3482 10 7026 10
Cerebrovascular disease 1754 5 1044 3 2779 4
Tuberculosis 553 2 409 1 947 1
Central nervous systemb 221 1 354 1 568 1
Gastrointestinal disease 2629 7 1294 4 3900 5
Other diseases 925 3 1078 3 1987 3
Total 36 623 50 35 933 50 72 556 100
Abbreviations: COPD¼ chronic obstructive pulmonary diseases; SES¼ socioeco-
nomic status. aPatients may suffer from more than one condition. bDementia in 96%
of these patients.
Table 2 Distribution of cancer patients newly diagnosed in 1997–2006
according to gender, age and socioeconomic status (SES)
Males Females
o70 70+ o70 70+
Tumour
localisation
No. of
patients
% low
SES
No. of
patients
% low
SES
No. of
patients
% low
SES
No. of
patients
% low
SES
Oesophagus 589 23 342 37 170 30 161 43
Stomach 767 26 719 37 386 31 465 44
Colorectal 3176 21 2662 32 2266 24 2630 40
Pancreas 433 24 339 36 325 28 374 44
Lung 4498 29 3827 38 2226 35 923 50
Melanoma 563 15 169 33 729 16 194 43
Breast — — — — 9070 21 3094 42
Cervix uteri — — — — 476 37 120 43
Corpus uteri — — — — 1189 25 576 42
Ovary — — — — 875 23 438 42
Prostate 3930 20 4149 30 — — — —
Kidney 639 22 392 32 372 31 300 41
Urinary
bladder
855 25 1027 33 216 32 308 40
Non-Hodgkin’s
lymphoma
1060 21 575 31 703 25 514 42
Total of
these sites
16 510 23 14 201 34 19 003 24 10 097 42
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A gradient towards more concomitant conditions appeared in
lower SES groups (Po0.001), which had a significantly higher
risk of cardiovascular disease (ORlow vs high SES¼ 1.4, 95% CI:
1.3–1.5), COPD (OR¼ 1.8 (1.7–1.9)), diabetes mellitus (OR¼ 1.5
(1.4–1.6)), cerebrovascular disease (OR¼ 1.5 (1.4–1.7)), tuber-
culosis (OR¼ 1.3 (1.1–1.6)), dementia (OR¼ 1.3 (1.0–1.8)),
gastrointestinal disease (OR¼ 1.5 (1.4–1.6)), and two or more
concomitant conditions (OR¼ 1.8 (1.7–1.9)) in addition to their
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Figure 1 Number of concomitant diseases among cancer patients diagnosed in 1997–2006 in the Southeastern Netherlands. *Distribution of number of
concomitant diseases significantly different from the highest socioeconomic status category.
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cancer (Table 3). The risk of having cancer and also at least
one other serious concomitant disease was 50% higher in the low
SES than in the high SES group (OR¼ 1.5 (1.4–1.6)).
For four concomitant conditions we stratified by tumour
localisation (Figure 2). The risk of cardiovascular disease among
low compared with high SES patients was significantly higher
(1.4–1.6 times) for patients with stomach, colorectal, lung, breast,
prostate, and bladder cancer. The risk of COPD was elevated
among low SES patients with cancer of the stomach, colorectum,
pancreas, lung, breast, corpus uteri, prostate, and kidney
(OR’s ranging from 1.4 to 2.2). The risk of diabetes mellitus
was highest among people from low SES with breast cancer
(OR¼ 2.0 (1.2–2.4)) and the risk of gastrointestinal diseases
was highest among patients with oesophageal cancer (OR¼ 2.0
(1.2–3.4)).
Crude 1-year survival of cancer patients from lower SES was
worse compared with the highest SES for all tumour sites
combined and for the major sites separately (Table 4). The age-
adjusted risk of death was significantly elevated for both men
(HRlow vs high SES¼ 1.40, 95% CI: 1.3–1.4) and women (HR 1.40
(1.3–1.5)). Adding comorbidity to the model reduced HR to 1.35
Table 3 Risk of specific concomitant diseases according to SES adjusted
for age and gender among cancer patients diagnosed in 1997–2006
SES
Concomitant disease Low Intermediate High Pa
Previous cancer 1.01 0.99 1.00 0.7
Cardiovascular disease 1.42b 1.23b 1.00 0.0001
COPD 1.81b 1.37b 1.00 0.0001
Hypertension 0.98 1.03 1.00 0.2
Diabetes mellitus 1.52b 1.32b 1.00 0.0001
Cerebrovascular disease 1.53b 1.27b 1.00 0.0001
Tuberculosis 1.34b 1.17 1.00 0.01
Central nervous system 1.34b 1.05 1.00 0.05
Gastrointestinal 1.48b 1.27b 1.00 0.0001
Other 1.22b 1.10 1.00 0.01
1 or more concomitant disease 1.50b 1.24b 1.00 0.0001
2 or more concomitant diseases 1.80b 1.36b 1.00 0.0001
Abbreviations: COPD¼ chronic obstructive pulmonary diseases; SES¼ socio-
economic status. aP for overall effect of SES (w2-likelihood ratio). bConfidence
interval does not include 1.00.
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0.00 2.502.001.501.000.50
0.00 2.502.001.501.000.50 0.00 2.502.001.501.000.50
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Figure 2 Risk of four concomitant diseases among cancer patients with the lowest socioeconomic status (SES) compared with those with the highest SES
(¼ reference, 1.00) according to tumour localisation with adjustment for age and gender. *95% confidence interval does not include 1.00; # No reliable
estimate because o5 cases in reference category.
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for men and 1.34 for women. The relative contribution of
comorbidity in explaining the inequality in 1-year survival varied
from 0% for lung cancer to 33% among female colorectal cancer
patients.
DISCUSSION
To our knowledge, this is the first large population-based study to
demonstrates the impact of SES on the prevalence of concomitant
diseases among cancer patients, with increased prevalence of
comorbidity in lower socioeconomic strata for each type of cancer.
Cancer patients with low SES had a 50% higher risk of suffering
from at least one other serious disease compared with those with
high SES. The prevalence of comorbidity was significantly higher
with newly diagnosed cancer of lower compared with higher SES
for all 14 cancer sites studied. The diseases significantly related to
SES among cancer patients were cardiovascular disease, COPD,
diabetes mellitus, cerebrovascular disease, tuberculosis, diseases of
the central nervous system, and gastrointestinal disease. Although
both the prevalence of comorbidity and the proportional distri-
bution of SES vary significantly among tumour types, the gradient
of more comorbidity from high to low SES was apparent among
all tumour types.
Smoking is probably responsible for the higher risk of
cardiovascular disease, COPD, and cerebrovascular disease among
low SES groups (Doll et al, 1994; Stellman and Resnicow, 1997).
This is confirmed by the higher prevalence of those diseases
among patients with smoking-related tumours: cancers of the
stomach, lung, bladder, and kidney (Janssen-Heijnen et al, 1998;
Koppert et al, 2004). Diabetes was more frequent among low SES
for patients with cancers of the colorectum, pancreas, lung, breast,
corpus uteri or prostate, or melanoma or NHL. Diabetes has been
linked to pancreas cancer (Jain et al, 1991; Kalapothaki et al, 1993)
either as a risk factor or as the clinical manifestation of the cancer
itself (Warshaw and Fernandez-del Castillo, 1992). Diabetes has
also been associated with an increased risk for breast (Xue and
Michels, 2007), endometrial (Parazzini et al, 1991), and colorectal
cancer (Polednak, 2006) probably because of a relation with
obesity (Reeves et al, 2007). Substantial evidence exists for the
association of obesity with low SES (Sobal and Stunkard, 1989;
Wardle et al, 2002; McLaren, 2007).
The prevalence of gastrointestinal diseases was highest for low
SES patients with oesophageal, colorectal, lung, breast, prostate or
kidney cancer, or NHL. Oesophageal cancer has also been
associated with gastrointestinal diseases (Koppert et al, 2004).
A lower consumption of vegetables, fruit, and fibres, which may
protect from oesophageal (Tzonou et al, 1996; Terry et al, 2001b)
and colorectal cancer (Pietinen et al, 1999; Michels et al, 2000;
Voorrips et al, 2000; Terry et al, 2001a; Bueno-de-Mesquita et al,
2002; Flood et al, 2002), has been reported among lower SES
(Wallstrom et al, 2000; Hulshof et al, 2003; Wardle and Steptoe,
2003).
We used an indicator of SES based on the postal code of
a residential area. This aggregate covers a very small geo-
graphical area, and thus represents a reliable approximation of
individual SES. Furthermore, routinely collected income tax
data (no questionnaires or interviews) have been found to
provide reliable estimates of household income. Previous studies
have proven that socioeconomic differences based on neigh-
bourhood data tend to reflect such differences well at the
individual level (Bos et al, 2000, 2001; Smits et al, 2001).
Furthermore, this objective measure of SES is also applicable to
older women (born before 1955), whose occupation or education
does not always properly reflect their social class (Berkman and
Macintyre, 1997).
Previously, we found that patients with comorbidity were
often treated less aggressively, if alternative treatment strategies
were available. Except for patients with a tumour with poor
survival, comorbidity has an independent prognostic effect
(Janssen-Heijnen et al, 2005). This negative impact of comorbidity
on survival of cancer might have several mechanisms: the
increased risk of death due to the comorbid condition itself, more
contra-indications for the cancer treatment, more indications for
dose reduction and a higher rate of treatment-related complica-
tions such as infections and cardiovascular events. In several of
our recent studies, the adverse effects of comorbidity on survival
appeared to be independent of treatment, so less aggressive
treatment could not (fully) account for the observed differences
in survival between patients with and without comorbidity
(Post et al, 2001; Lemmens et al, 2005; Louwman et al, 2005;
van Spronsen et al, 2005; Houterman et al, 2006). As SES
represents a combination of lifestyle, health, and risk of
suboptimal treatment, cancer patients with comorbidity could
also (partly) explain the poorer prognosis. Although an in-depth
study remains necessary to reveal whether stage at diagnosis
and treatment contributed to the SES gradient in survival, also
for longer survival periods, our preliminary analyses demonstrated
a clear gradient in 1-year survival rates, which could partly
be attributed to comorbidity.
Table 4 Crude survival, risk of death, and contribution of comorbidity to risk of death according to tumour site and SES among cancer patients diagnosed
in 1997–2006
1-year survival rate (%) Model Aa Model Ba
Relative contribution
Low SES Inter-mediate High SES HRc (95% CI) HRc (95% CI) comorbidityb
Males
Colorectum 72 78 78 1.13 (1.0–1.3) 1.10 (1.0–1.3) 23%
Lung 36 39 41 1.11 (1.0–1.2) 1.11 (1.0–1.2) 0%
Prostate 90 94 95 1.47 (1.2–1.8) 1.36 (1.1–1.7) 22%
Totald 59 66 70 1.40 (1.3–1.5) 1.35 (1.3–1.4) 12%
Females
Colorectum 74 78 79 1.09 (0.9–1.3) 1.06 (0.9–1.2) 33%
Lung 41 42 46 1.09 (1.0–1.2) 1.09 (1.0–1.2) 0%
Breast 94 97 98 1.68 (1.3–2.2) 1.56 (1.2–2.0) 18%
Totald 74 81 84 1.40 (1.3–1.5) 1.34 (1.3–1.4) 15%
aModel A: adjusted for age, Model B: adjusted for age and the presence of concomitant diseases (yes vs no). b((HR model A(HR model A+comorbidity))/(1HR model
A)) 100. cHazard Ratio (HR) of lowest socioeconomic status (SES) group compared with highest (¼ reference). dAll studied sites combined (oesophagus, stomach,
colorectum, pancreas, lung, melanoma, breast, cervix uteri, corpus uteri, ovary, prostate, kidney, urinary bladder, non-Hodgkin’s lymphoma).
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Our study shows considerable variation in comorbidity
by tumour type and a higher risk of concomitant disease
among patients from lower SES. Given the aetiology of the
type of tumours as well as the aetiology of the concomitant
diseases that occur more frequently among patients from low
SES background, a lot can probably be gained from preventive
measures related to lifestyle (such as smoking and obesity).
Considering survival is worse for patients of low SES, our
results stress the need for reduction of socioeconomic differences
in health.
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